24th EVF Scientific Programme
- 24th Meeting of the European Venous Forum
- Royal Olympic Hotel, Athens, Greece – 27-29 June 2024
- Click here to download the Programme
THURSDAY 27 JUNE 2024
| 08.00-08.30 | ePoster Presentations
(5 minute presentation, 5 minute discussion) Chair: Niels Baekgaard (Denmark) |
| 08.00-08.10 eP1 | Positive Post-test Probability Value Of The Wells Score In Deep Vein Thrombosis Diagnostic According To Its Prevalence.
Ilya Schastlivtsev*1; Kirill Lobastov1; Sergey Tsaplin2; Nikita Burlov3; Maxim Kuznetsov4; Astanda Bargandzhiya1; Sergey Zhuravlev2; Grigory Rodoman1 |
| 08.10-08.20 eP2 | 24 months follow up of patients with deep vein thrombosis, treated with sulodexide as adjuvant during the acute and long term post thrombotic event.
Erasto Aldrett Lee*; Nora Lecuona Huet. Grupo de Atención Vascular Integral, San Luis Potosí, Mexico |
| 08.20-08.30 eP3 | A Novel And Breakthrough Way To Collect Thrombosis Risk Assessment Data
Atul Laddu1; Rishi Motkur1; Anish Joshi1; Nethra Pai1; Krish Raina1; Nysha Reddy1; Joseph Caprini2; Jibran Bokhary*1 |
| 08.30-10.30 | Abstract Session 1: VTE, Stents
(10 minute presentation, 10 minute discussion) Chairs: Andrew Nicolades (Cyprus), Stavros Kakkos (Greece) |
| 08.30-08.50 1.1 | Hormonal contraception use and the risk of venous thromboembolism after minimally invasive varicose vein surgery: Insight from the CAPSIVS trial.
Mariya Shaldina*1; Kirill Lobastov2; Olga Dzhenina3; Denis Borsuk1; Ilya Schastlivtsev2; Astanda Bargandzhiya2; Alexey Fokin1. 1South Ural State Medical University, Chelyabinsk, Russia; 2Pirogov Russian National Research Medical University, Moscow, Russia; 3First Phlebological Center, Moscow, Moscow, Russia Submitted for the EVF Prize |
| 08.50-09.10 1.2 | The role of rivaroxaban in the prevention of post thrombotic syndrome.
Christos Karathanos*; Konstantinos Spanos; Georgios Volakakis; Athanasios Chaidoulis; Konstantinos Tzimas-Dakis; Alexandros Barpatis; Konstantinos Mpatzalexis; Georgios Kouvelos; Miltiadis Matsagas; Athanasios Giannoukas. University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessa, Larissa, Greece |
| 09.10-09.30 1.3 | Non-invasive molecular MR imaging enables staging of fibrosis and monitoring response to statin treatment in the deep vein thrombosis.
Ling Gao*1; Nadia Chaher2; Joana P Cartaxo Serralha1; Carlos Velasco1; Gastão Cruz3; Claudia Prieto1; Claudia Prieto4; René M Botnar1; René M Botnar4; Alberto Smith1; Alkystis Phinikaridou1; Prakash Saha1. 1King’s College London, London, UK; 2King’s College London, London, UK; 3University of Michigan, Michigan, USA; 4Pontificia Universidad Católica de Chile, Santiago, Chile |
| 09.30-09.50 1.4 | Comparison of oral rivaroxaban and warfarin in patients with inferior vena cava filter: a retrospective cohort study.
Ilya Schastlivtsev*1; Alexey Pankov2; Sergey Tsaplin2; Eugeniy Stepanov1; Sergey Zhuravlev2; Kirill Lobastov1. 1Pirogov Russian National Research Medical University, Moscow, Russia; 2Clinical Hospital No. 1 of the President’s Administration of the Russian Federation, Moscow, Russia |
| 09.50-10.10 1.5 | Five-year outcomes of dedicated venous stents for the treatment of acute and chronic iliofemoral venous obstructive disease.
Rachael Morris*1; Anna Pouncey2; Kanoklada Srikuea1; Narayan Karunanithy1; Narayanan Thulasidasan1; Prakash Saha1; Taha Khan1; Stephen Black1. 1St Thomas’ Hospital, London, UK; 2Imperial College, London, UK Submitted for the EVF Prize |
| 10.10-10.30 1.6 | Deep venous stent failure: the St Thomas’ classification and predictors of reintervention in chronic disease.
Ehsanul K Choudhury*1; Rachael I Morris1; Anna L Pouncey2; Kanoklada Srikuea3; Taha Khan1; Bhavesh Natha1; Narayanan Thulasidasan1; Narayan Karunaninthy1; Stephen A Black1. 1St. Thomas’ Hospital, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK; 2Imperial College London, London, UK; 3Thammasat University Hospital, Pathum Thani, Thailand Submitted for the EVF Prize |
| 10.30-11.00 | Refreshments. Visit Exhibition |
| 11.00-13.00 | Abstract Session 2: Varicose Veins
(10 minute presentation, 10 minute discussion) Chairs: Marianne Vandendreissche (Belgium), Eberhard Rabe (Germany) |
| 11.00-11.20 2.1 | Ten-year outcomes of a randomised controlled trial of endovenous laser ablation versus conventional surgery for great saphenous varicose veins.
Abduraheem Mohamed*1; Daniel Carradice1; Ian Chetter1; George Smith1; Tom Wallace2; Shivani Rae1; Bharadhwaj Ravindhran1; Arthur Lim1; Alexander Knighton1. 1Hull York Medical School, Hull, UK; 2Leeds General Infirmary, Leeds, UK Submitted for the EVF Prize |
| 11.20-11.40 2.2 | Synchronous prophylactic ablation of the AASV in patients undergoing thermal GSV ablation significantly reduces the recurrence rate – 12-month follow-up data for the SYNCHRONOUS Trial.
Tobias Hirsch*1; Carmen Dietrich2; Karsten Hartmann3; Thomas Mattausch4; Philipp Zollmann5; Hans-Christian Wenzel4; Jürgen Veltmann6; Thomas Weiler7; Guido Lengfellner8; Lars Müller9; Felizitas Pannier10; Lorenz Uhlmann2; Markus Stücker11; Christine Müller-Christmann2 1Practice for Internal Medicine and Vascular Diseases, Halle, Germany; 2University of Heidelberg, Heidelberg, Germany; 3Vein Center Freiburg, Freiburg, Germany; 4Vein Center Leipzig, Leipzig, Germany; 5Venenzentrum Zollmann, Jena, Jena, Germany; 6Venenzentrum Dr. Zollmann, Jena, Jena, Germany; 7Venencentrum Pfortzheim, Pfortzheim, Germany; 8Venenzentrum Dr. Lengfellner und Koll. Regensburg, Regensburg, Germany; 9Dermatologicum Hamburg, Hamburg, Germany; 10Privatpraxis Dr. Pannier, Bonn, Germany; 11University of Bochum, Bochum, Germany |
| 11.40-12.00 2.3 | Patterns of recurrence in recurrent varices after surgery (REVAS): A systematic review and network meta-analysis.
Konstantinos Kavallieros*; Giannis Konstantinou; Emmanuel Giannas; Iris Soteriou; Turner Benedict; Adam Gwozdz; Alun Davies. Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK Submitted for the EVF Prize |
| 12.00-12.20 2.4 | Impact of thermographic imaging on clinical decision making for patients with superficial venous disease.
Fedor Lurie*1; Kate Gates2. 1Jobst Vascular Institute and the University of Michigan, Toledo, USA; 2Jobst Vascular Institute, Toledo, USA |
| 12.20-12.40 2.5 | Role of compression after radiofrequency ablation of varicose veins: longer term follow-up of randomised controlled trial.
Chee Yee Hew*1; Damien Mcelvenny2; Madu Onwudike3. 1Manchester University NHS Foundation Trust, Manchester, UK; 2Centre for Occupational and Environmental Health, University of Manchester, Manchester, UK; 3Bolton Hospitals NHS Foundation Trust, UK, Manchester, UK Submitted for the EVF Prize |
| 12.40-13.00 2.6 | Endovenous welding: 5-year experience of using a new thermal method with automatic ablation mode.
Larysa Chernukha*1; Vladyslav Horbovets2; Sofiia-Solomiia Horbovets2; Melnychuk Hlib2. 1Shalimov National Institute of Surgery and Transplantology of NAMS of Ukraine, Kyiv, Ukraine; 2Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine |
| 13.00-14.00 | Lunch. Visit Exhibition |
| 14.00-15.00 | Industry Session 1 |
| 15.00-16.00 | Didactic Session 1: Venous Thromboembolism, AI
Chairs: Armando Mansilha (Portugal), Tomasz Urbanek (Poland) |
| 15.00-15.15 | The controversy on treating calf DVT. Stavros Kakkos (Greece) |
| 15.15-15.30 | What is the destiny of the deep femoral vein after iliofemoral thrombus removal. Niels Baekgaard (Denmark) |
| 15.30-15.45 | Thrombus extraction versus thrombolysis. Efthymios Avgerinos (Greece) |
| 15.45-16.00 | The use of artificial intelligence (AI) in phlebology today and tomorrow. Albert Claude Benhamou (France) |
| 16.00-16.30 | Refreshments and Visit Exhibition |
| 16.30-17.30 | Industry Session 2 |
| 17.30-18.30 | Didactic Session 2: Post-thrombotic Syndrome
Chairs: Efthymios Avgerinos (Greece), Marzia Lugli (Italy) |
| 17.30-17.45 | Can we prevent PTS? Tomasz Urbanek (Poland) |
| 17.45-18.00 | Pelvic congestion syndrome. Mark Whiteley (UK) |
| 18.00-18.15 | Complex cases of reflux and obstruction. Houman Jalaie (Germany) |
| 18.15-18.30 | Organising a wound treatment centre in 2024 for vascular surgeons and phlebologists. Arkadiusz Jawien (Poland) |
| 18.30-19.30 | Welcome Reception |
FRIDAY 28 JUNE 2024
| 08.00-08.30 | ePoster Presentations
(5 minute presentation, 5 minute discussion) Chair: Erica Mendoza (Germany) |
|
| 08.00-08.10 eP4 | Prevalence Of Chronic Venous Disease And Quality Of Life In The Greek Population. Efthymios D Avgerinos*1; Spyros N Vasdekis2; Dimitrios G Kardoulas2; Garyfallia Stefanou3; Georgia Kourlaba4; Antonios Papageorgiou5 1Attikon Hospital, University of Athens and Athens Medical Center, Athens, Greece; 2Attikon Hospital, University of Athens, Athens, Greece; 3EconCare LP, Athens, Greece; 4University of Peloponnese, Athens, Greece; 5Athens Navy Hospital, Athens, Greece |
|
| 08.10-08.20 eP5 | Efficacy Of Micronized Purified Flavonoid Fraction (MPFF) In Reducing Lower-limb Symptoms In Patients At All Stages Of Chronic Venous Disease: A Systematic Literature Review And Meta-analysis. Stavros Kakkos1; Kirill Lobastov2; Alejandro Ochoa Gonzalez3; Sriram Narayanan4; Lianrui Guo5; Andrew Nicolaides*6 1University of Patras Medical School, Patras, Greece; 2Pirogov Russian National Research Medical University, Moscow, Russia; 3Hospital Centro Medico del Noroeste, San Luis Río Colorado, Mexico; 4The Harley Street Heart and Vascular Centre, Singapore, Singapore; 5Xuanwu Hospital, Capital Medical University, Beijing, China; 6Vascular Screening and Diagnostic Centre and University of Nicosia Medical School, Nicosia, Cyprus |
|
| 08.20-08.30 eP6 | Professional Liability And Patient Safety In Thromboembolic Disease. Mar Oller Grau*1; Enric Roche Rebollo2 1Hospital General de Catalunya, Barcelona, Spain; 2Hospital Universitari General de Catalunya, Barcelona, Spain |
|
| 08.30-10.30 | Abstract Session 3: Miscellaneous
(10 minute presentation, 10 minute discussion) Chairs: Albert-Claude Benhamou (France), Marianne Vandendriessche (Belgium) |
|
| 08.30-08.50 3.1 | Short term cost effectiveness of radiofrequency ablation and high ligation/stripping for great saphenous vein incompetence.
Oskar Nelzén*1; Johan Skoog2; Lars Bernfort3; Helene Zachrisson4. 1Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Linköping, Sweden; 22Department of Clinical Physiology in Linköping, and Department of Health, Medicine and Caring Scien, Linköping, Sweden; 3Department of Health, Medicine and Caring Sciences, Linköping, Sweden; 4Department of Clinical Physiology in Linköping, and Department of Health, Medicine and Caring Science, Linköping, Sweden |
|
| 08.50-09.10 3.2 | The DAVE randomised clinical trial — decellularised dermis allograft for the treatment of chronic venous leg ulceration.
Matthew Tan*1; Sarah Onida1; Valeria Balan1; Francine Heatley1; Sarrah Peerbux1; Tristan Lane1; David Epstein2; Keith Poskitt3; Nicky Cullum4; John Norrie5; Robert Lee5; Akila Chandrasekar6; Richard Lomas6; Alun Davies1. 1Imperial College London, London, UK; 2University of Granada, Granada, Spain; 3Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UK; 4University of Manchester, Manchester, UK; 5University of Edinburgh, Edinburgh, UK; 6NHS Blood and Transfusion, Bristol, UK Submitted for the EVF Prize |
|
| 09.10-09.30 3.3 | An open-label first in man usability and safety investigation with an intravenous injection technique to deploy tumescence during laserablation of the great saphenous vein.
Michael Akesson*1; Anders Lundell2. 1Department of Clinical Sciences Lund, Lund University, Sweden., Malmo, Sweden; 2Lund University, Lund, Sweden |
|
| 09.30-09.50 3.4 | 3 years experience and follow up of varixio foam ecoguided procedure in great saphenous veins and tributaries.
Giovanni Alongi*; Giovanni Alongi. Angiocor, Palermo, Italy Submitted for the EVF Prize |
|
| 09.50-10.10 3.5 | Status of the superficial lymphatic system in patients with chronic venous disease as detected by ICG-lymphography.
Marina Demekhova*1; Kirill Lobastov2; Igor Sonkin3; Tatiyana Gurina4; Astanda Bargandzhiya2. 1NMRC of Oncology named after N.N.Petrov of MoH of Russia, Saint Petersburg, Russia; 2Pirogov Russian National Research Medical University, Moscow, Russia; 3Road Clinical Hospital of JSC “Russian Railways”, Saint Petersburg, Russia; 4Phlebocentr Private Clinic, Kaliningrad, Russia Submitted for the EVF Prize |
|
| 10.10-10.30 3.6 | Investigating the role of LL37 in accelerating atherosclerosis following venous thrombosis.
Joana P. Cartaxo Serralha*1; Ling Gao1; Maria L. Bertolaccini1; Alexandru Dregan1; Joachim Pircher2; Alkystis Phinikaridou1; Christian Schulz2; Alberto Smith1; Prakash Saha1. 1King’s College London, London, UK; 2Klinikum der Universität München, Munich, Germany Submitted for the EVF Prize |
|
| 10.30-11.00 | Refreshments | |
| 11.00-12.00 | Industry Session 3 | |
| 12.00-12.30 | EVF Invited Lecture: | |
| Introduction: Stavros Kakkos (Greece) | ||
| Perioperative Management of Patients on Vitamin K Antagonists and Direct Oral Anticoagulants: Present and Future Perspectives. Alex Spyropoulos (USA) | ||
| 12.30-13.30 | Lunch. Visit Exhibition | |
| 13.30-14.10 | Prize winning papers from the American Vein and Lymphatic Society and Japanese Society of Phlebology
(10 minute presentation, 10 minute discussion) Chairs: Stephen Black (UK), Mark Malouf (Australia) |
|
| 13.30-13.50 Pr1 | Identification of Outcomes in Clinical Studies for Pelvic Venous Disease: A Scoping Review.
Adam Gwozdz. Department of Surgery, Imperial College London, UK |
|
| 13.50-14.10 Pr2 | Investigation of risk point of the great saphenous vein-saphenous nerve in the treatment of lower extremity varicose veins.
Katsushi Oda*. Kochi Vein Care Clinic, Kochi, Japan |
|
| 14.10-14.30 | International Guidelines 2024 on VTE: Highlights and Controversies. Andrew Nicolaides (Cyprus) | |
| 14.30-15.30 | Industry Session 4 | |
| 15.30-16.00 | Refreshments and Visit Exhibition | |
| 16.00-17.30 | Joint EVF/AVF/ESVS/ Session
Chairs: George Geroulakos (Greece), Ruth Bush (USA) |
|
| AVF Leadership: | ||
| 16.00-16.15 | Influence of SFJ reflux on venous symptomatology: Current and future research. Ruth Bush (USA) | |
| 16.15-16.30 | Recognition of the anterior accessory saphenous vein in primary and recurrent venous disease. Kathleen Ozsvath (USA) | |
| ESVS Leadership: | ||
| 16.30-16.45 | Misconceptions regarding elastic compression in DVT patients for prevention of PTS. Armando Mansilha (Portugal) | |
| 16.45-17.00 | Long term freedom from recurrent superficial venous disease after thermal ablation, open surgery, foam sclerotherapy and mechanochemical ablation. Maarit Venermo (Finland) | |
| EVF Leadership | ||
| 17.00-17.15 | High risk superficial vein thrombosis. Athanasios Giannoukas (Greece) | |
| 17.15-17.30 | Complications of interventions and recurrence. Imre Bihari (Hungary) | |
| 17.30-17.45 | Invited Presentation: Comparing cyanoacrylate sealing closure with thermal ablation and surgical stripping: first results of the SPECTRUM Study programme. Tobias Hirsch (Germany) | |
| 17.45-18.45 | Annual General Meeting (members only) | |
| 20.00 | Congress Dinner | |
SATURDAY 29 JUNE 2024
| 08.00-08.30 | ePoster Presentations
(5 minute presentation, 5 minute discussion) Chair: Efthymios Avgerinos (Greece) |
| 08.00-08.10 eP7 | A First In Human Study: In-vivo Venous Leg Ulcer Metabolomic Profiling Using A Rapid Evaporative Ionisation Mass Spectrometry (REIMS) Coupled With The Hydrosurgical Debridement System Kanin Pruekprasert*; Matthew Tan; Daniel Simon; Lauren Ford; Alun Davies; Zoltan Takats; Sarah Onida. Imperial College London, London, UK |
| 08.10-08.20 eP8 | Atypical Forms Of Lower Limb Varicose Veins Nina Mzhavanadze*; Roman Kalinin; Igor Suchkov; Kristina Pshennikova; Viktor Korbut; Ruslan Khashumov; Ivan Shanaev. Ryazan State Medical University, Ryazan, Russia |
| 08.30-08.30 eP9 | Reversal Of Age-related Endothelial Dysfunction In The Arterial And Venous Vasculature In Rats By Micronized Purified Flavonoid Fraction (MPFF) With Improvement Of The Nitric Oxide/Reactive Oxygen Species Imbalance Said Amissi1; Hira Muzammel1; Ali Mroueh1; Ibrahima Diouf1; Dalseong Gong1; Walaa Fakih1; Abdul Qureshi1; Eric Mayoux2; Valérie Schini-Kerth*1 1Strasbourg University, Strasbourg, France; 2Institut de Recherche International Servier, Suresnes, France |
| 08.30-10.30 | Abstract Session 4: PTS, Haemodynamics of Iliac Occlusion, Venoactive Drugs
10 minute presentation, 10 minute discussion) Chairs: Marzia Lugli (Italy) |
| 08.30-08.50 4.1 | Non-operative management of post thrombotic syndrome: a systematic review and meta-analysis of the evidence from 2000-2023.
Ehsanul K Choudhury*1; Alena Abraham2; Elif I Okten2; Taha Khan1; Stephen A Black1. 1St. Thomas’ Hospital, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK; 2King’s College London, London, UK |
| 08.50-09.10 4.2 | Incidence and treatment of pelvic congestion syndrome in patients with varicose veins.
Christos Dimopoulos*1; Ioannis Papastefanou2; Panagiotis Theodoridis1; Nikolaos Iatrou1; Theodosios Bisdas1. 1Athens Medical Center, Athens, Greece; 2King’s College London, London, UK |
| 09.10-09.30 4.3 | Direct measurement of the hemodynamic impact of iliac vein stenosis: a pre-clinical study.
Fedor Lurie*1; Todd Russell2; Yusuf Nawras3. 1Jobst Vascular Institute and the University of Michigan, Toledo, USA; 2Jobst Vascular Institute, Toledo, USA; 3University of Toledo, Toledo, USA |
| 09.30-09.50 4.4 | Acquired arteriovenous fistulas in patients with symptomatic chronic iliac vein occlusion.
Yuji Hoshino*; Hiroyoshi Yokoi. Fukuoka Sanno Hospital, Fukuoka, Japan |
| 09.50-10.10 4.5 | Vitis vinifera leaf extract improves the quality of life in patients with chronic venous insufficiency (CVI): a prospective, randomized, double-blind, controlled study.
Foteini Psachoulia*1; Christos Karathanos2; Georgios Sfyroeras1; Konstantinos Antonopoulos1; Georgios Kouvelos2; Dimitrios Kardoulas1; Christina Chania3; Christina Petropoulou3; Aikaterini Argyropoulou3; Phaedra-E. Bokari3; Miltiadis Matsagkas2; Nikolaos Adamopoulos4; Alexios-L. Skaltsounis3; Ioannis Kakisis1; Athanasios Giannoukas2; Ioanna Andreadou3; Georgios Geroulakos1. 1Athens University Medical School, Attikon University Hospital, Athens, Greece; 2Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, Greece; 3National and Kapodistrian University of Athens (NKUA), Athens, Greece; 4Galenica S.A., Athens, Greece |
| 10.10-10.30 4.6 | Effectiveness of micronized purified flavonoid fraction-based treatment in patients with chronic venous disease: meta-analysis of data from vein act prolonged observational studies.
Vadim Bogachev*1; Boris Kvasnikov2; Olga Linnik2. 1Pirogov Russian National Research Medical University, Moscow, Russia; 2Servier, Moscow, Russia |
| 10.30-11.00 | Refreshments and Visit Exhibition |
| 11.00-12.00 | Joint EVF/BVF Session
Chairs: Athanasios Giannoukas (Greece), Sorin Olariu (Romania) |
| 11.00-11.15 | Crossectomy. Dominik Heim (Switzerland) |
| 11.15-11.30 | Complications and adverse events in superficial venous treatments. Christos Karathanos (Greece) |
| 11.30-11.45 | Conservative treatment vs thrombus removal for Iliofemoral vein thrombosis in patients with congenital abnormalities of the inferior vena cava. Vangelis Alexiou (Greece) |
| 11.45-12.00 | Differences in the diagnosis and management of FAVA and glomuvenous malformations. George Geroulakos (Greece) |
| 12.00-13.00 | Didactic Session 3 / Abstract Session 5: New Devices, Varicose Veins and Technology
(10 minute presentation, 5 minute discussion) Chairs: Erika Mendoza (Germany), Eberhard Rabe (Germany) |
| 12.00-12.15 | News on foam, screening, tumescence and ulcer healing. Dominik Heim (Switzerland) |
| 12.15.12.30 | There is an undercurrent of cyanoacrylate adhesive ablation opposition out there. Is there a problem with glue? Mark Malouf (Australia) |
| 12.30-12.45 5.3 | 3D ultrasound: applications of new technology in the study of venous pathology.
Edoardo Cervi*1; Giovanni Alongi2; Mattia Paletti3; Marika Delai4. 1Università degli Studi di Brescia, Brescia, Italy; 2Angiocor, Messina, Palermo, Agrigento, Italy; 3Poliambulanza, Brescia, Italy; 4University of Brescia, Brescia, Italy |
| 12.45-13.00 5.4 | High intensity focused ultrasound in treating great saphenous vein incompetence: perioperative and 1-year outcomes.
Paolo Casoni*1; Emanuele Nanni1; Matteo Pizzamiglio2. 1Ippocrate vein Academy, PARMA, Italy; 2Ippocrate Vein Academy, Parma, Italy |
| 13.00-14.00 | Lunch and Visit Exhibition |
| 14.00-15.00 | Didactic Session 4: Varicose Veins, Imaging, Stenting
Chairs: Niels Baekgaard (Denmark), Dominik Heim (Switzerland) |
| 14.00-14.15 | Anatomy of lower extremity veins – should we revise the undergraduate teaching? Marian Simka (Poland) |
| 14.15-14.30 | The anatomy of the anterior accessory saphenous vein. Alberto Caggiati (Italy) |
| 14.30-14.45 | The benefits of 3D imaging in phlebology. Mario Sica (France) |
| 14.45-15.00 | Current status of stenting in chronic iliofemoral obstruction. Stephen Black (UK) |
| 15.00-16.00 | Abstract Session 6: Miscellaneous
(10 minute presentation, 5 minute discussion) Chairs: Imre Bihari (Hungary), Stavros Kakkos (Greece) |
| 15.00-15.15 6.1 | Preclinical chronic animal study to evaluate percutaneous selective closure or percutaneous closure combined with foam injection in superficial veins.
Edoardo Cervi*1; Gastone Bergamaschi2. 1Università degli Studi di Brescia, Brescia, Italy; 2Garofalo Health Care Clinic, Vicenza, Italy |
| 15.15-15.30 6.2 | Inflammatory and apoptotic markers in Covid-19 patients on anticoagulant therapy
Igor Suchkov*; Roman Kalinin; Andrey Agapov; Nina Mzhavanadze; Vladislav Povarov; Aleksandr Nikiforov; Denis Maksaev; Artyom Chobanian. Ryazan State Medical University, Ryazan, Russia |
| 15.30-15.45 6.3 | An evidence based anatomical classification of incompetent calf perforator veins using ultrasound analysis of over 10,000 individual vessels.
Barrie Price*; Tim Fernandez-Hart; Charmaine Harrison; Judy Holdstock; Mark Whiteley. The Whiteley Clinic, Guildford, UK |
| 15.45-16.00 6.4 | Early results of the treatment for saphenous incompetence using cyanoacrylate glue together with foam sclerotherapy.
Marian Simka*. University of Opole, Opole, Poland |
| 16.00-16.30 | End of Meeting. Presentation of 2025 Meeting. Tomasz Urbanek (Poland) |